Patient-derived xenografts (PDX) are preclinical models for precision cancer medicine. PDX models are highly recognized for recapitulating phenotype-genotype associations of their matched patient ...

Cambridge, UK, 26 May 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today announced it has added four BRAF-resistant ...

Researchers from the National Health Research Institutes of Taiwan described the efficacy of BPR1J481, a multitarget tyrosine kinase inhibitor in PDX-derived colorectal cancer cells, which retain the ...

Assessing risk of recurrence for nonmetastatic triple-negative breast cancer (TNBC) is a key determinant of therapeutic strategy. The best predictor of recurrence risk is failure to achieve a ...

Patient-derived xenografts (PDX) may accurately predict early recurrence and survival outcomes in triple negative breast cancer (TNBC), offering a potential tool for tailoring treatment strategies to ...

Figure 1: Design, preparation, and therapeutic mechanisms of PPCi NPs. (A) Self-assembly process of PPCi NPs. The opposite electrical properties of PEG- PEI (positively charged) and siRNA (negatively ...

New research from Dr. Seungjae Lee, Dr. Eric Lai, and their collaborators points to a potential opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially ...

An exhaustive pre-clinical study of a circRNA drug candidate (cmRNA1210) encoding IL-12sc for anti-tumor therapeutics. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

A team of researchers in China has developed a novel nanomedicine that precisely targets gastric cancer cells, significantly inhibiting tumor growth while showing minimal toxicity. Published in Nano ...